Outcomes of COVID-19 Patients under Cytotoxic Cancer Chemotherapy in Brazil.

ABSTRACT: Cancer patients present a distinct vulnerability to COVID-19. It is unclear if chemotherapy could accentuate the overall risk in these patients. We performed a retrospective analysis linking COVID-19 data and oncological information systems to compare lethality in patients undergoing cytotoxic chemotherapy before COVID-19. We considered patients who received chemotherapy in the last 30 days as in "active treatment", and patients who did not receive drugs in this period as "non-active treatment" for propensity-score pair matching. We also tested the influence of baseline variables in our results in a multivariate model. 66.1% (162/246) of patients in matched active chemotherapy died vs. 70.2% (172/246) in the matched non-active chemotherapy group. The risk of death was positively associated

SUBMITTER: Duarte MBO 

PROVIDER: S-EPMC7760330 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature